Navigation Links
Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
Date:6/12/2008

Study Showing Results of Tengion Neo-Bladder Augment(TM) to be Featured in

July Issue of the Journal of Urology

EAST NORRITON, Pa., June 12 /PRNewswire/ -- Tengion, Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-tissues, announced today that the results of a preclinical research study conducted with its Neo-Bladder Augment(R) will be featured in the July issue of the Journal of Urology, Vol. 180. The paper, "Early Cellular and Stromal Responses in Regeneration Versus Repair of a Mammalian Bladder Using Autologous Cell and Biodegradable Scaffold Technologies," was co-authored by Tengion scientists Manuel J. Jayo, D.V.M., Ph.D., Deepak Jain, Ph.D., Belinda J. Wagner, Ph.D. and Timothy A. Bertram, D.V.M., Ph.D.

Key findings of the preclinical trial -- in which either a Tengion Neo-Bladder Augment or a biodegradable mesh scaffold alone was surgically implanted following partial, trigone-sparing cystectomy and both groups were evaluated clinically at one, three, six and nine months -- show that the Tengion Neo-Bladder Augment restored baseline urodynamics as early as six months after implantation and led to a structurally and functionally complete regenerated bladder wall as early as nine months. In contrast, scaffold implants alone failed to return to urodynamic baseline by the study termination and failed to regenerate a complete bladder wall.

"We continue to see great promise in our neo-bladder research programs and these latest data underscore the potential of Tengion's Autologous Organ Regeneration Platform(TM) to provide a neo-organ that allows the body to regenerate a functional organ," said Dr. Bertram, Senior Vice President, Science and Technology of Tengion. "We are looking forward to formally sharing these findings with our peers and continuing to develop our Neo-Bladder Augment and the Tengion Neo-Bladder Replacement(R) to meet the critical patient needs that exist today."

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create neo-organs or neo-tissues that are designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
4. Brain Stem Cells Can Be Awakened, Say Schepens Scientists
5. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
6. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
7. Neuroscientists Offer Hope for Breast Cancer Patients Suffering From Chemobrain
8. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
9. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
10. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
11. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... the U.S. Food and Drug Administration (FDA) has ... for SB-318, a single treatment strategy intended to ... (MPS I). The SB-318 IND application is now ... 1/2 clinical study (SB-318-1502) designed to assess the ...
(Date:2/5/2016)... , Feb. 5, 2016  Despite the recent ... slower than other industries to embrace Big Data due ... utilization. On the medical side, organizations have begun looking ... from clinical trials to adherence. --> ... benchmarking firm Best Practices, LLC, Big Data has started ...
(Date:2/5/2016)... , Feb. 5, 2016  As people age, ... The multitude of recommended screenings and tests that are ... a priority. However, for the majority of aging individuals, ... health planning. For the 37.5 million American adults who ... the present to make hearing health a 2016 healthy ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... The Association of Home ... and the Home Health and Hospice ICD-10 Transition Workgroup are working closely with ... guidance and clarifications, to address concerns over the use of 'A' as the ...
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is ... this country. The AutismOne 2016 Conference, which is being held May 25-29 at the ... hear elsewhere about helpful interventions and causes of chronic illness in children. , Very ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... the latest techniques and the most minimally invasive approaches. , Women who have ... after menopause. Other risk factors include surgery to the pelvic floor, connective tissue ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
Breaking Medicine News(10 mins):